Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with the general population in nine industrialized countries

International Journal of Epidemiology

Volumn 38, Issue 6, 2009, Pages 1624-1633

  Egger, Matthias ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antiretroviral therapy; General population; HIV infection; Industrialized countries; Meta analysis; Mortality; Standardized mortality ratio

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

COHORT ANALYSIS; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; META-ANALYSIS; MORTALITY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MULTICENTER STUDY; PHYSIOLOGY; PREVALENCE; RISK FACTOR; SUBSTANCE ABUSE; VIROLOGY;

EUROPE; NORTH AMERICA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MORTALITY; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 75349103546     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp306     Document Type: Article

References (50)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-99.
2. Hogg RS, Yip B, Kully C et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;160:659-65.
3. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
4. Lewden C, Raffi F, Chene G, Sobel A, Leport C. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. AIDS 2001;26:480-82.
5. Jaggy C, von Overbeck J, Ledergerber B et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003;362:877-78.
6. Keiser O, Taffe P, Zwahlen M et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004;18: 1835-43.
7. Jensen-Fangel S, Pedersen L, Pedersen C et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004;18:89-97.
8. van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. AIDS 2005;40:212-18.
9. Anon. Life insurance in short supply for people with HIV/AIDS. AIDS Policy & Law 2002;17:5.
10. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
11. Chene G, Sterne JA, May M et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362:679-86.
12. May M, Royston P, Egger M, Justice AC, Sterne JA. ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2003;23:2375-98.
13. May MT, Sterne JA, Costagliola D et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006;368:451-58.
14. Centers for Disease Control. Revision of case definition of acquired immunodeficiency syndrome for national reporting-United States. MMWR 1985;34:373-75.
15. Chiang CL. The Life Table And Its Applications. Malabar, FL: Robert E. Krieger Publishing Company, 1984.
16. Lundgren JD, Phillips AN, Vella S et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:153-60.
17. Nieuwkerk PT, Sprangers MA, Burger DM et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-68.
18. Binquet C, Chene G, Jacqmin-Gadda H et al. Modeling changes in CD4-positive T-lymphocyte counts after the tart of highly active antiretroviral therapy and the relation with risk of opportunistic infections The Aquitaine Cohort, 1996-1997. Am J Epidemiol 2001;153: 386-93.
19. Becker SL, Raffanti SR, Hansen NI et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr 2001;26:72-81.
20. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-38.
21. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000;133: 401-10.
22. D'Arminio MA, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507.
23. Fatkenheuer G, Theisen A, Rockstroh J et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-16.
24. Jaen A, Casabona J, Esteve A et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc) 2005;124:525-31.
25. Mocroft A, Barry S, Sabin CA et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999;13:1255-61.
26. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12:2161-67.
27. Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004;39: 1380-84.
28. Sterne JA, May M, Sabin C et al. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr 2007;46:607-15.
29. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.
30. Jha P, Ranson MK, Nguyen SN, Yach D. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am J Public Health 2002;92:1002-06.
31. Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV-positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16: 1663-71.
32. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004;164:1214-20.
33. Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. CMAJ 2005;173:160-64.
34. Martinez E, Milinkovic A, Buira E et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007;8:251-58.
35. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356: 1800-05.
36. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 2004;364:83-94.
37. Nylen G, Mortimer J, Evans B, Gill N. Mortality in young adults in England and Wales: the impact of the HIV epidemic. AIDS 1999;13:1535-41.
38. Centers for Disease Control and Prevention. QuickStats: age-adjusted death rates* for human immunodeficiency virus (HIV) infection, by sex-United States, 1987-2003. MMWR 2005;54:1188.
39. Borrell C, Pasarin MI, Cirera E, Klutke P, Pipitone E, Plasencia A. Trends in young adult mortality in three European cities: Barcelona, Bologna and Munich, 1986-1995. J Epidemiol Community Health 2001;55:577-82.
40. WHO Mortality Database. http://www3.who.int/whosis/mort (1 August 2009, date last accessed).
41. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519-28.
42. Rehm J, Greenfield TK, Rogers JD. Average volume of alcohol consumption, patterns of drinking, and all-cause mortality: results from the US National Alcohol Survey. Am J Epidemiol 2001;153:64-71.
43. Katzmarzyk PT, Janssen I, Ardern CI. Physical inactivity, excess adiposity and premature mortality. Obes Rev 2003; 4:257-90.
44. Gnavi R, Petrelli A, Demaria M, Spadea T, Carta Q, Costa G. Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-up. Int J Epidemiol 2004;33:864-71.
45. Lewden C, Chene G, Morlat P et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-77.
46. Anon. Holland: companies to offer life insurance to people living with HIV/AIDS. HIV/AIDS Policy & Law Rev./Canadian HIV/AIDS Legal Network 2005;21:75-76.
47. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ. Applying public health principles to the HIV epidemic. N Engl J Med 2005;353:2397-402.
48. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:329-32.
49. Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005;330:1301-02.
50. Paltiel AD, Weinstein MC, Kimmel AD et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 2005;352:586-95.